Skip to main content
News Tag: RTOG 9802
NRG Oncology Currents October 2019 eNewsletter
Read More
Analyses of NRG Oncology/RTOG 9802 Suggests Both IDH-mutant WHO-defined Molecular Subgroups of High-risk Low-Grade Gliomas May Benefit from the Addition of PCV Chemotherapy to Radiotherapy
Read More